Shire gets EU nod to make Replagal in Lexington
This article was originally published in Scrip
Executive Summary
Shire has received approval from the EMA for the purification of its Fabry disease enzyme replacement therapy Replagal (agalsidase alfa) at its new facility in Lexington, Massachusetts. The firm says that it will be able to meet current and anticipated additional demand for the product, which was already being purified at its facility in Alewife, Cambridge, Massachusetts.